Clinical research status of eszopiclone

doi:10.12092/j.issn.1009-2501.2019.11.014

Abstract

Abstract:

Eszopiclone is a non-benzodiazepine sedative and hypnotic agent, which plays a sedative and hypnotic effects by regulating GABA receptor through isomerism, with the affinity to the central benzodiazepine receptor in about 50 times stronger than zopiclone, with less adverse reaction and toxicity. Eszopiclone has been approved by Food and Drug Administration (FDA) of United States for the treatment of insomnia in 2004. In recent years, with the popularization of clinical application, relevant clinical research data are constantly updated. In clinical practice, it could be used not only for primary insomnia, but also for the comorbid insomnia accompanied by sleep apnea syndrome, depression, post-traumatic stress disorder, perimenopausal and postmenopausal women. It is worthy to take a brief review on the clinical literatures of eszopiclone in order to provide a updated introduction for the clinicians.

Key words: eszopiclone, sedative hypnotics, insomnia

CLC Number:

R971+.3

JIA Min, HUANG Jinsha, LIU Qunhui, WANG Tao. Clinical research status of eszopiclone[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(11): 1300-1304.

References

［1］Monti JM，Pandi-Perumal SR. Eszopiclone: its use in the treatment of insomnia［J］. Neuropsychiatr Dis Treat，2007, 3: 441-453.
［2］Wilson S, Anderson K, Baldwin D,et al. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: An update［J］. Psychopharmacolog，2019,33（8）:923-947.
［3］Huedo-Medina TB，Kirsch I，Middlemass J，et al． Effectiveness of non-benzodiazepine hypnotics in treatment of adult insomnia: meta-analysis of data submitted to the Food and Drug Administration［J］． Brit Med J，2012,345: e8343.
［4］Pinto LR Jr, Bittencourt LR, Treptow EC, et al. Eszopiclone versus zopiclone in the treatment of insomnia［J］. Clinics, 2016,71(1): 5-9.
［5］Smith PR，Sheikh KL，Costan-Toth C，et al． Eszopiclone and zolpidem do not afect the prevalence of the low arousal threshold phenotype［J］．J Clin Sleep Med，2017, 13: 115-119.
［6］Matheson E,Hainer BL.Insomnia: pharmacologic therapy［J］.Am Fam Physician,2017,96(1):29-35.
［7］Dixon CL，Harrison NL，Lynch JW，et al. Zolpidem and eszopiclone prime alpha1beta2gamma2 GABAA receptors for longer duration of activity［J］． Brit J Pharmacol，2015, 172: 3522-3536.
［8］Tariq SH，Pulisetty S．Pharmacotherapy for insomnia［J］．Clin Geriatr Med, 2008, 24(1): 93-105．
［9］Najib J. Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia［J］. Clin Ther, 2006, 28(4): 491-516.
［10］Schroeck JL, Ford J, Conway EL, et al. Review of safety and efficacy of sleep medicines in older adults［J］. Clin Ther, 2016, 38(11):2340-2372.
［11］Wu F,Zhao XL,Wei MJ,et al.Pharmacokinetics and safety of eszopiclone in healthy Chinese volunteers［J］.Arzneimittelforschunq,2012,62(12):561-565.
［12］Halas CJ. Cost-effectiveness of eszopiclone for treatment of chronic insomnia［J］. Expert Rev Pharmacoecon Outcomes Res, 2007, 7(1): 9-17.
［13］Abad VC, Guilleminault C. Insomnia in elderly patients: Recommendations for pharmacological management［J］． Drugs Aging, 2018, 35(9): 791-817.
［14］Liang L,Huang Y,Xu R,et al.Eszopiclone for the treatment of primary insomnia:a systematic review and meta-analysis of double-blind,randomized,placebo-controlled trials［J］.Sleep Medicine,2019,62:6-13.
［15］Roth T，Walsh JK，Krystal A，et al． An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia［J］． Sleep Med，2005, 6: 487-495.
［16］Botteman MF，Ozminkowski RJ，Wang S，et al． Cost effectiveness of long-term treatment with eszopiclone for primary insomnia in adults: a decision analytical model［J］． CNS Drugs，2007, 21: 319-334.
［17］Uchimura N，Kamijo A，Takase T． Effects of eszopiclone on safety，subjective measures of efficacy，and quality of life in elderly and nonelderly Japanese patients with chronic insomnia，both with and without comorbid psychiatric disorders: a 24-week，randomized，double-blind study［J］．Ann Gen Psychiatry, 2012, 11(1): 15. doi: 10.1186/1744-859X-11-15.
［18］Rsner S, Englbrecht C, Wehrle R, et al. Eszopiclone for insomnia［J］. Cochrane Database Syst Rev.2018; 10:CD010703. doi:10.1002/14651858.CD010703.pub2.
［19］Lettieri CJ, Quast TN, Eliasson AH, et al. Eszopiclone improves overnight polysomnography and continuous positive airway pressure titration: a prospective, randomized, placebo-controlled trial［J］. Sleep, 2008, 31(9): 1310-1316.
［20］Mason M, Cates CJ, Smith I. Effects of opioid, hypnotic and sedating medications on sleep-disordered breathing in adults with obstructive sleep apnoea［J］. Cochrane Database Syst Rev, 2015, (7): CD011090. doi: 10.1002/14651858.CD011090.pub2.
［21］Eckert DJ, Owens RL, Kehimann GB, et al. Eszopiclone increases the respiratory arousal threshold and lowers the apnoea/hypopnoea index in obstructive sleep apnoea patients with a low arousal threshold［J］. Clinical Science, 2011, 120(12): 505-514.
［22］Mason M, Welsh EJ, Smith I. Drug therapy for obstructive sleep apnoea in adults［J］. Cochrane Database Systematic Reviews, 2013,31(5): CD003002.
［23］Edwards BA, Sands SA, Owens RL. et al. The combination of supplemental oxygen and a hypnotic markedly improves obstructive sleep apnea in patients with a mild to moderate upper airway collapsibility［J］. Sleep, 2016, 39(11): 1973-1983.
［24］Kishi T,Matsunaga S,Iwata N.Efficacy and tolerability of Z-drug adjunction to antidepressant treatment for major depressive disorder:a systematic review and mata-analysis of randomized controlled trials［J］.Eur Arch Psychiatry Clin Neurosci,2017,267(2):149-161.
［25］Pollack MH，Hoge EA，Worthington JJ，et al．Eszopiclone for the treatment of posttraumatic stress disorder and associated insomnia: a randomized，double-blind，placebo-controlled trial［J］．J Clin Psychiat, 2011; 72: 892-897.
［26］Soares CN,Joffe H,Rubens R,et al.Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomized controlled trial ［J］.Obstetricians Gynecology,2006,108(6):1402-1410.
［27］Joffe H, Petrillo L, Viquera A, et al. Eszopiclone improves insomnia and depressive and anxious symptoms in perimenopausal and postmenopausal women with hot flashes: a randomized, double-blinded, placebo-controlled crossover trial［J］. Am J Obsretrics Gynecol, 2010, 202(2): 171.e1-e11.
［28］Menza M， Dobkin RD， Marin H， et al． Treatment of insomnia in Parkinson's disease: A controlled trial of eszopiclone and placebo［J］．Movement Disorders, 2010, 25(11): 1708-1714.
［29］Trotti LM, Bliwise DL. Treatment of the sleep disorders associated with Parkinson's disease［J］. Neurotherapeutics, 2014, 11(1): 68-77.
［30］Olireira P, Coroa M, Madeira N. Treatment options for insomnia in schizophrenia: A systematic review［J］. Pharmacopsychiatry, 2019, 52(4): 165-169.
［31］李亚玲, 叶建飞, 李婷,等. 右佐匹克隆合并艾司西酞普兰治疗广泛性焦虑伴失眠的对照研究［J］. 中国临床药理学与治疗学, 2014, 19（1）：54-57.
［32］Roth T, Price JM, Amato DA, et al. The effect of eszopiclone in patients with insomnia and coexisting rheumatoid arthritis: a pilot study［J］. Prim Care Companion J Clin Psychiatry, 2009,11(6): 292-301.
［33］Yao L, Ramirez AD, Roecker AJ, et al. The dual orexin receptor antagonist, DoRA-22, lowers histamine levels in the lateral hypothalamus and prefrontal cortex without lowering hippocampal acetylcholine［J］. J Neurochem, 2017, 142(2): 204-214.
［34］Guzowski JF, McNaughton BL, Barnes CA, et al. Environment-specific expression of the immediate-early gene Arc in hippocampal neuronal ensembles ［J］. Nat Neurosci, 1999, 2(12):1120-1124.
［35］Uslaner JM, Tye SJ, Eddins DM, et al. Orexin receptor antagonists differ from standard sleep drugs by promoting sleep at doses that do not disrupt cognition［J］. Sci Transl Med, 2013, 5(179): 179ra44.
［36］Hair PI, McCormack PL, Curran MP. Eszopiclone:a review of its use in the treatment of insomnia［J］. Drugs, 2008,68: 1415-1434.
［37］Halas CJ. Eszopicolne ［J］.Am J Health Syst Pharm, 2006, 63: 41-48.
［38］Treves N, Perlmman A, Kolenberg Geron L, et al. Z-drugs and risk for falls and fractures in older adults-a systemayic review and meta-analysis［J］. Age Ageing, 2018, 47(2): 201-208.

[1]	ZHAO Zhengqing, LI Yanpeng, XIANG Xiaoxia, ZHUANG Jianhua, ZHAO Zhongxin. Pathophysiology and cognitive behavioral therapy of chronic insomnia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(5): 482-486.
[2]	LI Yanpeng, ZHAO Zhengqing, WANG Wenwen, ZHUANG Jianhua, ZHAO Zhongxin. Progress in clinical diagnosis and drug treatment of chronic insomnia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(5): 487-490.
[3]	CAI Dandan, GUI Donghui, ZHANG Jianbing, ZHOU Wenhua. Clinical efficacy of low dose risperidone combined with trazodone in the treatment of heroin addicts during detoxification [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(1): 94-98.
[4]	LI Ya-ling, YE Jian-fei, LI Ting , LI Guo-rong. The control research of escitalopram with or without eszopiclone on the treatment of generalized anxiety disorder with insomnia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(1): 54-57.
[5]	LI Tao. Some problems on clinical trails evalution of herbs medicine for insomnia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(4): 375-378.